Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance

AIDS

Volumn 18, Issue 12, 2004, Pages 1691-1696

  Ross, Lisa ^a   Parkin, Neil ^b   Chappey, Colombe ^b   Fisher, Robin ^a   St Clair, Marty ^a   Bates, Michael ^b   Tisdale, Margaret ^c   Lanier, Ernest Randall ^a  

^a GLAXOSMITHKLINE   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Algorithm; M184V; TAM; Thymidine analog mutation

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS MUTATION; WILD TYPE;

ADENINE; ALGORITHMS; ANTI-HIV AGENTS; DATABASES, GENETIC; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV; HIV INFECTIONS; HUMANS; MUTATION; ORGANOPHOSPHORUS COMPOUNDS; PHENOTYPE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; THYMIDINE; ZALCITABINE; ZIDOVUDINE;

EID: 4143088125     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131355.44834.e4     Document Type: Article

References (29)

1. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.
2. Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR, et al. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucl Acids Res 1997; 25:4532-4536.
3. Rezende LF, Curr K, Ueno T, Mitsuya H, Prasad VR. The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity. J Virol 1998; 72: 2890-2895.
4. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000; 74:3579-3585.
5. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999; 179:92-100.
6. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, et al. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patientsÒ AIDS 1996; 10:975-981.
7. Wainberg MA. Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials. Leukemia 1997; 11 (Suppl. 3):85-88.
8. Ail-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, et al. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002; 16:1686-1689.
9. Whitcomb JM, Parkin NT, Chappey C, Hellman NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.
10. Miller MD, Margot NA, Hertogs K, Larder B, Miller V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleoside Nucleotide Nucl Acids 2001; 20: 1025-1028.
11. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
12. Moyle GJ, Gazzard BG. Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine. AIDS 2001; 15:799-800.
13. Petropoulos CI, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928.
14. Parkin NT, Hellmann NS, Whitcomb JM Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wildtype human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004, 48:437-443.
15. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004, 189:837-846.
16. Kantor R, Machekano R, Gonzales MI, Dupnik K, Schapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucl Acids Res 2001; 29:296-299.
17. Ravela J, Betts BJ, Brun-Vezinet F, Vandamme AM, Descamps D, van Laethem K, et al. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquired Immune Defic Syndr 2003; 33:8-14.
18. Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, Petropoulos CJ. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquired Immune Defic Syndr 2003; 31:128-136.
19. Kaufmann D, Pantaleo G, Sudre P Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study [Letter]. Lancet 1998; 351:723-724.
20. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour ID, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with delectable viremia. N Engl J Med 2001; 44:472-480.
21. Miller V, Stark T, Loeliger AE, Lange JM. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med 2002; 3:135-145.
22. Back NK, Berkhout B. Limiting deoxynucleoside triphosphale concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1997; 41:2484-2491.
23. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15: 4040-4049.
24. Boyer PL, Hughes SH. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1995; 39:1624-1628.
25. Sharma PL, Crumpacker CS. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J Virol 1999; 73:8448-8456.
26. Devereux HL, Emery VC, Johnson MA Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001; 65:218-224.
27. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123-F127.
28. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001; 6:115-126
29. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CI. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188:992-1000.